![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SPAG17 |
Gene summary for SPAG17 |
![]() |
Gene information | Species | Human | Gene symbol | SPAG17 | Gene ID | 200162 |
Gene name | sperm associated antigen 17 | |
Gene Alias | CT143 | |
Cytomap | 1p12 | |
Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | Q6Q759 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
200162 | SPAG17 | PTC06 | Human | Thyroid | PTC | 4.17e-03 | 1.36e-01 | 0.2057 |
200162 | SPAG17 | ATC13 | Human | Thyroid | ATC | 1.50e-35 | 6.29e-01 | 0.34 |
200162 | SPAG17 | ATC5 | Human | Thyroid | ATC | 1.46e-39 | 6.82e-01 | 0.34 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00991115 | Thyroid | PTC | microtubule-based transport | 88/5968 | 190/18723 | 2.08e-05 | 2.08e-04 | 88 |
GO:009911112 | Thyroid | ATC | microtubule-based transport | 91/6293 | 190/18723 | 2.97e-05 | 2.48e-04 | 91 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SPAG17 | SNV | Missense_Mutation | novel | c.197N>A | p.Ser66Asn | p.S66N | Q6Q759 | protein_coding | deleterious(0) | possibly_damaging(0.691) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
SPAG17 | SNV | Missense_Mutation | c.1954N>C | p.Met652Leu | p.M652L | Q6Q759 | protein_coding | tolerated(0.26) | benign(0) | TCGA-A2-A0D1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD | |
SPAG17 | SNV | Missense_Mutation | novel | c.2997G>C | p.Lys999Asn | p.K999N | Q6Q759 | protein_coding | deleterious(0.01) | possibly_damaging(0.553) | TCGA-A2-A3XT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | PR |
SPAG17 | SNV | Missense_Mutation | c.2122N>G | p.Asn708Asp | p.N708D | Q6Q759 | protein_coding | tolerated(0.75) | benign(0) | TCGA-A7-A0DA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
SPAG17 | SNV | Missense_Mutation | novel | c.6057N>A | p.Asp2019Glu | p.D2019E | Q6Q759 | protein_coding | deleterious(0.04) | benign(0.38) | TCGA-A8-A08R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SPAG17 | SNV | Missense_Mutation | novel | c.3282G>T | p.Glu1094Asp | p.E1094D | Q6Q759 | protein_coding | tolerated(0.08) | benign(0.009) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SPAG17 | SNV | Missense_Mutation | novel | c.6184N>T | p.Ala2062Ser | p.A2062S | Q6Q759 | protein_coding | deleterious(0) | possibly_damaging(0.857) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
SPAG17 | SNV | Missense_Mutation | c.3603N>T | p.Glu1201Asp | p.E1201D | Q6Q759 | protein_coding | tolerated(0.06) | probably_damaging(0.994) | TCGA-AR-A251-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
SPAG17 | SNV | Missense_Mutation | novel | c.1354N>A | p.Glu452Lys | p.E452K | Q6Q759 | protein_coding | deleterious(0) | probably_damaging(0.953) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SPAG17 | SNV | Missense_Mutation | c.4564G>T | p.Ala1522Ser | p.A1522S | Q6Q759 | protein_coding | deleterious(0.04) | possibly_damaging(0.706) | TCGA-BH-A0BZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | CR |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |